MedDataX Logo

Tiotropium / Respimat One Year Study in COPD.

NCT ID: NCT00387088

Last Updated: 2014-05-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3991 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tiotropium / Respimat One-Year Study

NCT00168844

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Tiotropium / Respimat One-Year Study

NCT00168831

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Tiotropium Respimat Pharmacokinetic Study in COPD

NCT01222533

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE2

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT00281567

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tiotropium

Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)

Group Type OTHER

Tiotropium

Intervention Type DRUG

Placebo

Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)

Group Type OTHER

Respimat

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Respimat

Intervention Type DEVICE

Tiotropium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female
2. At least 40 years old
3. Smoker or ex-smoker
4. Smoking history \> 10 pack-years
5. Forced Expiratory Volume in 1 Second (FEV1) \< 60% predicted

Exclusion Criteria

1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
2. History of asthma or allergic conditions.
3. Malignancy requiring treatment within past 5 years
4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
5. Known active tuberculosis
6. Known hypersensitivity to anticholinergic drugs.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

205.372.01012 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

205.372.01020 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

205.372.01062 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

205.372.01048 Boehringer Ingelheim Investigational Site

Berkeley, California, United States

Site Status

205.372.01037 Boehringer Ingelheim Investigational Site

Huntington Park, California, United States

Site Status

205.372.01058 Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Site Status

205.372.01059 Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Site Status

205.372.01007 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

205.372.01034 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

205.372.01028 Boehringer Ingelheim Investigational Site

Rancho Mirage, California, United States

Site Status

205.372.01011 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

205.372.01066 Boehringer Ingelheim Investigational Site

Boulder, Colorado, United States

Site Status

205.372.01008 Boehringer Ingelheim Investigational Site

Norwalk, Connecticut, United States

Site Status

205.372.01004 Boehringer Ingelheim Investigational Site

Brandon, Florida, United States

Site Status

205.372.01060 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

Site Status

205.372.01069 Boehringer Ingelheim Investigational Site

Miami Beach, Florida, United States

Site Status

205.372.01023 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Site Status

205.372.01053 Boehringer Ingelheim Investigational Site

Winter Park, Florida, United States

Site Status

205.372.01045 Boehringer Ingelheim Investigational Site

Calhoun, Georgia, United States

Site Status

205.372.01043 Boehringer Ingelheim Investigational Site

Normal, Illinois, United States

Site Status

205.372.01061 Boehringer Ingelheim Investigational Site

Dubuque, Iowa, United States

Site Status

205.372.01035 Boehringer Ingelheim Investigational Site

Wichita, Kansas, United States

Site Status

205.372.01049 Boehringer Ingelheim Investigational Site

Shreveport, Louisiana, United States

Site Status

205.372.01015 Boehringer Ingelheim Investigational Site

Biddeford, Maine, United States

Site Status

205.372.01067 Boehringer Ingelheim Investigational Site

Columbia, Maryland, United States

Site Status

205.372.01006 Boehringer Ingelheim Investigational Site

Rockville, Maryland, United States

Site Status

205.372.01013 Boehringer Ingelheim Investigational Site

Detroit, Michigan, United States

Site Status

205.372.01003 Boehringer Ingelheim Investigational Site

Minneapolis, Minnesota, United States

Site Status

205.372.01021 Boehringer Ingelheim Investigational Site

Chesterfield, Missouri, United States

Site Status

205.372.01014 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

205.372.01036 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

205.372.01046 Boehringer Ingelheim Investigational Site

Albuquerque, New Mexico, United States

Site Status

205.372.01024 Boehringer Ingelheim Investigational Site

Mineola, New York, United States

Site Status

205.372.01029 Boehringer Ingelheim Investigational Site

Rochester, New York, United States

Site Status

205.372.01030 Boehringer Ingelheim Investigational Site

Syracuse, New York, United States

Site Status

205.372.01026 Boehringer Ingelheim Investigational Site

Chapel Hill, North Carolina, United States

Site Status

205.372.01019 Boehringer Ingelheim Investigational Site

Charlotte, North Carolina, United States

Site Status

205.372.01027 Boehringer Ingelheim Investigational Site

Elizabeth City, North Carolina, United States

Site Status

205.372.01038 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

Site Status

205.372.01031 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

205.372.01017 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

205.372.01041 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

205.372.01044 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

205.372.01001 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

205.372.01063 Boehringer Ingelheim Investigational Site

Eugene, Oregon, United States

Site Status

205.372.01068 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

205.372.01056 Boehringer Ingelheim Investigational Site

Swathmore, Pennsylvania, United States

Site Status

205.372.01039 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

205.372.01050 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

205.372.01005 Boehringer Ingelheim Investigational Site

Fort Worth, Texas, United States

Site Status

205.372.01018 Boehringer Ingelheim Investigational Site

Killeen, Texas, United States

Site Status

205.372.01040 Boehringer Ingelheim Investigational Site

New Braunfels, Texas, United States

Site Status

205.372.01052 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

205.372.01022 Boehringer Ingelheim Investigational Site

Danville, Virginia, United States

Site Status

205.372.01065 Boehringer Ingelheim Investigational Site

Lynchburg, Virginia, United States

Site Status

205.372.01055 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

205.372.01064 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

205.372.61002 Woolcock Institute of Medical Research

Glebe, New South Wales, Australia

Site Status

205.372.61009 Thoracic & General Physician

Cairns, Queensland, Australia

Site Status

205.372.61005 Redcliffe Hospital

Redcliffe, Queensland, Australia

Site Status

205.372.61006 The Investigator Clinic

Port Lincoln, South Australia, Australia

Site Status

205.372.61007 The Burnside War Memorial Hospital

Toorak Gardens, South Australia, Australia

Site Status

205.372.61004 Boehringer Ingelheim Investigational Site

Woodville, South Australia, Australia

Site Status

205.372.61010 Ecru

Box Hill, Victoria, Australia

Site Status

205.372.61008 Geelong Clinical Research Centre

Geelong, Victoria, Australia

Site Status

205.372.61001 Emeritus Research

Malvern, Victoria, Australia

Site Status

205.372.61003 Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Site Status

205.372.55012 Universidade Federal de Santa Catarina

Florianópolis, , Brazil

Site Status

205.372.55009 Hospital das Clínicas de Goiânia

Goiânia, , Brazil

Site Status

205.372.55005 Hospital Geral Otávio de Freitas

Recife, , Brazil

Site Status

205.372.55001 INCOR e Hospital das Clínicas da Universidade de São Paulo

São Paulo - SP, , Brazil

Site Status

205.372.55010 Unidade de Coracao e Pulmao do Dto. de Medicina

São Paulo - SP, , Brazil

Site Status

205.372.55011 CEDOES - Diagnóstico e Pesquisa

Vitória, , Brazil

Site Status

205.372.11007 Heritage Medical Research Building

Calgary, Alberta, Canada

Site Status

205.372.11013 Calgary West Medical Centre

Calgary, Alberta, Canada

Site Status

205.372.11011 Hermitage Medicentre

Edmonton, Alberta, Canada

Site Status

205.372.11017 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

205.372.11020 Wetaskiwin Lung Laboratory

Wetaskiwin, Alberta, Canada

Site Status

205.372.11010 Dr. Kay Ho

Chilliwack, British Columbia, Canada

Site Status

205.372.11018 Pacific Lung Health Centre

Vancouver, British Columbia, Canada

Site Status

205.372.11005 Professional Corp. Respirology

Saint John, New Brunswick, Canada

Site Status

205.372.11009 White Hills Medical Clinic

St. John's, Newfoundland and Labrador, Canada

Site Status

205.372.11012 West Lincoln Memorial Hospital

Grimsby, Ontario, Canada

Site Status

205.372.11014 Dr. Robert Luton

London, Ontario, Canada

Site Status

205.372.11001 Niagara Clinical Research

Niagara Falls, Ontario, Canada

Site Status

205.372.11019 Allergy and Asthma Research Centre

Ottawa, Ontario, Canada

Site Status

205.372.11003 London Road Diagnostic Clinic and Medical Centre

Sarnia, Ontario, Canada

Site Status

205.372.11016 London Road Diagnostic Clinic and Medical Centre

Sarnia, Ontario, Canada

Site Status

205.372.11002 Centenary Respiratory Research Associates

Scarborough Village, Ontario, Canada

Site Status

205.372.11006 Clinique de médecine familiale de La Malbaie

La Malbaie, Quebec, Canada

Site Status

205.372.11004 Mount Royal Family Physicians

Saskatoon, Saskatchewan, Canada

Site Status

205.372.11015 Dr. Arun Nayar

Saskatoon, Saskatchewan, Canada

Site Status

205.372.86002 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

205.372.86003 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

205.372.86004 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

205.372.86009 Boehringer Ingelheim Investigational Site

Chengdu, Sichuan Province, , China

Site Status

205.372.86008 Boehringer Ingelheim Investigational Site

Chongqing, , China

Site Status

205.372.86001 Boehringer Ingelheim Investigational Site

Guangzhou, , China

Site Status

205.372.86010 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

205.372.86011 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

205.372.86012 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

205.372.86005 Boehringer Ingelheim Investigational Site

Shenyang, , China

Site Status

205.372.86006 Boehringer Ingelheim Investigational Site

Shenyang, , China

Site Status

205.372.86007 Boehringer Ingelheim Investigational Site

Wuhan, , China

Site Status

205.372.45004 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

Site Status

205.372.45005 Boehringer Ingelheim Investigational Site

Horsens, , Denmark

Site Status

205.372.45002 Boehringer Ingelheim Investigational Site

Hvidovre, , Denmark

Site Status

205.372.45001 Boehringer Ingelheim Investigational Site

København NV, , Denmark

Site Status

205.372.45003 Boehringer Ingelheim Investigational Site

Odense C, , Denmark

Site Status

205.372.45006 Boehringer Ingelheim Investigational Site

Silkeborg, , Denmark

Site Status

205.372.35804 Boehringer Ingelheim Investigational Site

Helsinki, , Finland

Site Status

205.372.35802 Boehringer Ingelheim Investigational Site

Jyväskylä, , Finland

Site Status

205.372.35803 Boehringer Ingelheim Investigational Site

Lahti, , Finland

Site Status

205.372.35801 Boehringer Ingelheim Investigational Site

Tampere, , Finland

Site Status

205.372.3318A Clinique du Parc

Castelnau-le-Lez, , France

Site Status

205.372.3318B Clinique du Parc

Castelnau-le-Lez, , France

Site Status

205.372.3304A Cabinet Médical

Chamalières, , France

Site Status

205.372.3301A Hôpital Gabriel Montpied

Clermont-Ferrand, , France

Site Status

205.372.3310A Centre Hospitalier

Denain, , France

Site Status

205.372.3314A Cabinet Médical

Grasse, , France

Site Status

205.372.3306A Hôpital Ambroise Paré

Marseille, , France

Site Status

205.372.3303A Hôpital Notre Dame de Bon Secours

Metz, , France

Site Status

205.372.3303B Hôpital Notre Dame de Bon Secours

Metz, , France

Site Status

205.372.3312A Cabinet Médical

Montigny-lès-Metz, , France

Site Status

205.372.3312B Cabinet Médical

Montigny-lès-Metz, , France

Site Status

205.372.3302A Centre Médical Erdre Saint Augustin

Nantes, , France

Site Status

205.372.3305A Cabinet Médical

Nice, , France

Site Status

205.372.3305B Cabinet Médical

Nice, , France

Site Status

205.372.3315A Hôpital Caremeau

Nîmes, , France

Site Status

205.372.3315B Hôpital Caremeau

Nîmes, , France

Site Status

205.372.3317A Cabinet de Pneumologie

Nîmes, , France

Site Status

205.372.3320A Polyclinique Les Fleurs

Ollioules, , France

Site Status

205.372.3320B Polyclinique Les Fleurs

Ollioules, , France

Site Status

205.372.3316A Clinique les Bleuets

Reims, , France

Site Status

205.372.3316B Clinique les Bleuets

Reims, , France

Site Status

205.372.3321A Centre Hospitalier

Saint-Gaudens, , France

Site Status

205.372.3321C Centre Hospitalier

Saint-Gaudens, , France

Site Status

205.372.3319A Institut Arnault Tzanck

Saint-Laurent-du-Var, , France

Site Status

205.372.3325A Cabinet Médical

Six Four Les Plages, , France

Site Status

205.372.3324A Cabinet Médical

Toulon, , France

Site Status

205.372.3309A Cabinet médical

Toulouse, , France

Site Status

205.372.3309B Cabinet médical

Toulouse, , France

Site Status

205.372.49002 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

205.372.49004 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

205.372.49013 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

205.372.49007 Boehringer Ingelheim Investigational Site

Bonn, , Germany

Site Status

205.372.49008 Boehringer Ingelheim Investigational Site

Bruchsal, , Germany

Site Status

205.372.49011 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

205.372.49012 Boehringer Ingelheim Investigational Site

Gelnhausen, , Germany

Site Status

205.372.49006 Boehringer Ingelheim Investigational Site

Gütersloh, , Germany

Site Status

205.372.49014 Boehringer Ingelheim Investigational Site

Hanover, , Germany

Site Status

205.372.49005 Boehringer Ingelheim Investigational Site

Kassel, , Germany

Site Status

205.372.49009 Boehringer Ingelheim Investigational Site

Minden, , Germany

Site Status

205.372.49010 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

205.372.49016 Boehringer Ingelheim Investigational Site

Weinheim, , Germany

Site Status

205.372.49015 Boehringer Ingelheim Investigational Site

Weyhe, , Germany

Site Status

205.372.49001 Boehringer Ingelheim Investigational Site

Wiesloch, , Germany

Site Status

205.372.49003 Boehringer Ingelheim Investigational Site

Witten, , Germany

Site Status

205.372.30001 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

205.372.30002 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

205.372.30003 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

205.372.30013 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

205.372.30015 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

205.372.30011 Boehringer Ingelheim Investigational Site

Corinth, , Greece

Site Status

205.372.30009 Boehringer Ingelheim Investigational Site

Heraklion-Crete, , Greece

Site Status

205.372.30007 Boehringer Ingelheim Investigational Site

Kalamaria, , Greece

Site Status

205.372.30005 Boehringer Ingelheim Investigational Site

Kavala, , Greece

Site Status

205.372.30004 Boehringer Ingelheim Investigational Site

Komotini, , Greece

Site Status

205.372.30019 Boehringer Ingelheim Investigational Site

Nafplion, , Greece

Site Status

205.372.30008 Boehringer Ingelheim Investigational Site

Serres, , Greece

Site Status

205.372.30014 Boehringer Ingelheim Investigational Site

Thebes, , Greece

Site Status

205.372.30006 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

205.372.30017 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

205.372.85203 Boehringer Ingelheim Investigational Site

Hong Kong, , Hong Kong

Site Status

205.372.85201 Boehringer Ingelheim Investigational Site

Kowloon, , Hong Kong

Site Status

205.372.36001 Boehringer Ingelheim Investigational Site

Budapest, , Hungary

Site Status

205.372.36002 Boehringer Ingelheim Investigational Site

Debrecen, , Hungary

Site Status

205.372.36004 Boehringer Ingelheim Investigational Site

Deszk, , Hungary

Site Status

205.372.36005 Boehringer Ingelheim Investigational Site

Érd, , Hungary

Site Status

205.372.36006 Boehringer Ingelheim Investigational Site

Mosonmagyaróvár, , Hungary

Site Status

205.372.36007 Boehringer Ingelheim Investigational Site

Sopron, , Hungary

Site Status

205.372.91005 Boehringer Ingelheim Investigational Site

Andhra Pradesh, , India

Site Status

205.372.91016 Boehringer Ingelheim Investigational Site

Andhra Pradesh, , India

Site Status

205.372.91003 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

205.372.91006 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

205.372.91017 Boehringer Ingelheim Investigational Site

Calicut,Kerala, , India

Site Status

205.372.91007 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

205.372.91010 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

205.372.91002 Boehringer Ingelheim Investigational Site

Coimbatore, , India

Site Status

205.372.91009 Boehringer Ingelheim Investigational Site

Gujarat, , India

Site Status

205.372.91011 Boehringer Ingelheim Investigational Site

indore,MP, , India

Site Status

205.372.91012 Boehringer Ingelheim Investigational Site

Maharashtra, , India

Site Status

205.372.91004 Boehringer Ingelheim Investigational Site

Mumbai, , India

Site Status

205.372.91008 Boehringer Ingelheim Investigational Site

Mumbai, , India

Site Status

205.372.91015 Boehringer Ingelheim Investigational Site

New Delhi, , India

Site Status

205.372.91014 Boehringer Ingelheim Investigational Site

Punjab, , India

Site Status

205.372.91013 Boehringer Ingelheim Investigational Site

Tamil Nadu, , India

Site Status

205.372.91001 Boehringer Ingelheim Investigational Site

Uttar Pradesh, , India

Site Status

205.372.35303 Boehringer Ingelheim Investigational Site

Mullingar, , Ireland

Site Status

205.372.39007 Boehringer Ingelheim Investigational Site

Bussolengo (vr), , Italy

Site Status

205.372.39012 Boehringer Ingelheim Investigational Site

Ferrara, , Italy

Site Status

205.372.39003 Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

205.372.39004 Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

205.372.39005 Boehringer Ingelheim Investigational Site

Milan, , Italy

Site Status

205.372.39008 Boehringer Ingelheim Investigational Site

Modena, , Italy

Site Status

205.372.39009 Boehringer Ingelheim Investigational Site

Orbassano (to), , Italy

Site Status

205.372.39001 Boehringer Ingelheim Investigational Site

Pisa, , Italy

Site Status

205.372.39010 Boehringer Ingelheim Investigational Site

Pordenone, , Italy

Site Status

205.372.39002 Boehringer Ingelheim Investigational Site

Prato (fi), , Italy

Site Status

205.372.39011 Boehringer Ingelheim Investigational Site

Roma, , Italy

Site Status

205.372.39006 Boehringer Ingelheim Investigational Site

Trieste, , Italy

Site Status

205.372.37001 Boehringer Ingelheim Investigational Site

Kaunas, , Lithuania

Site Status

205.372.37003 Boehringer Ingelheim Investigational Site

Kaunas, , Lithuania

Site Status

205.372.37002 Boehringer Ingelheim Investigational Site

Vilnius, , Lithuania

Site Status

205.372.60003 Boehringer Ingelheim Investigational Site

George Town, , Malaysia

Site Status

205.372.60007 Boehringer Ingelheim Investigational Site

Johor Bahru, , Malaysia

Site Status

205.372.60004 Boehringer Ingelheim Investigational Site

Kelantan Darul Naim, , Malaysia

Site Status

205.372.60005 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

205.372.60006 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

205.372.60001 Boehringer Ingelheim Investigational Site

Kuala Selangor, , Malaysia

Site Status

205.372.60002 Boehringer Ingelheim Investigational Site

Kuching, Sarawak, , Malaysia

Site Status

205.372.52018 Hospital Universitario de Chihuahua

Chihuahua City, , Mexico

Site Status

205.372.52017 Instituto Nacional de Enfermedades Respiratorias (INER)

Col. Seccion XVI, , Mexico

Site Status

205.372.52013 Sanatorio Henri Dunant

Cuernavaca, Mor. México, , Mexico

Site Status

205.372.52005 Hospital Civil Nuevo de Guadalajara

Guadalajara, , Mexico

Site Status

205.372.52009 Hospital Civil Antiguo

Guadalajara Jal., , Mexico

Site Status

205.372.52001 Hospital General del Estado de Sonora

Hermosillo, Sonora, , Mexico

Site Status

205.372.52014 Hospital Angeles de las Lomas

Huixquilucan Edo.Mex., , Mexico

Site Status

205.372.52004 Clínica de Mérida

Merida Yuc., , Mexico

Site Status

205.372.52016 Hospital General de Mexicali

Mexicali Baja California Norte, , Mexico

Site Status

205.372.52010 Hospital General Agustin O´Haran

Mérida Yucatán, , Mexico

Site Status

205.372.52002 Unidad de Investigación clínica en Medicina

Monterrey, Nuevo León, , Mexico

Site Status

205.372.52006 Hospital Universitario

Monterrey, Nuevo León, , Mexico

Site Status

205.372.52012 Hospital de Nuestra Señora de la Salud

San Luis Potosí City, , Mexico

Site Status

205.372.52003 Hospital "Angel Leaño"

Zapopan, Jal., , Mexico

Site Status

205.372.31009 Boehringer Ingelheim Investigational Site

Amsterdam, , Netherlands

Site Status

205.372.31006 Boehringer Ingelheim Investigational Site

Drachten, , Netherlands

Site Status

205.372.31001 Boehringer Ingelheim Investigational Site

Groningen, , Netherlands

Site Status

205.372.31011 Boehringer Ingelheim Investigational Site

Hoofddorp, , Netherlands

Site Status

205.372.31007 Boehringer Ingelheim Investigational Site

Leeuwarden, , Netherlands

Site Status

205.372.31004 Boehringer Ingelheim Investigational Site

Roosendaal, , Netherlands

Site Status

205.372.31003 Boehringer Ingelheim Investigational Site

Sneek, , Netherlands

Site Status

205.372.31012 Boehringer Ingelheim Investigational Site

Utrecht, , Netherlands

Site Status

205.372.31002 Boehringer Ingelheim Investigational Site

Voorburg, , Netherlands

Site Status

205.372.31008 Boehringer Ingelheim Investigational Site

Weerselo, , Netherlands

Site Status

205.372.31005 Boehringer Ingelheim Investigational Site

Winschoten, , Netherlands

Site Status

205.372.47002 Boehringer Ingelheim Investigational Site

Ålesund, , Norway

Site Status

205.372.47001 Boehringer Ingelheim Investigational Site

Sandvika, , Norway

Site Status

205.372.47003 Boehringer Ingelheim Investigational Site

Trondheim, , Norway

Site Status

205.372.35102 Hospital Fernando Fonseca

Amadora, , Portugal

Site Status

205.372.35101 Hospital Pulido Valente

Lisbon, , Portugal

Site Status

205.372.35104 Hospital de Santa Marta

Lisbon, , Portugal

Site Status

205.372.35103 Hospital de São João

Porto, , Portugal

Site Status

205.372.35105 Centro Hospitalar do Alto Minho, Estrada de Santa Luzia

Viana do Castelo, , Portugal

Site Status

205.372.65001 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

Site Status

205.372.65003 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

Site Status

205.372.65005 Boehringer Ingelheim Investigational Site

Singapore, , Singapore

Site Status

205.372.42102 Boehringer Ingelheim Investigational Site

Bratislava, , Slovakia

Site Status

205.372.42103 Boehringer Ingelheim Investigational Site

Nové Zámky, , Slovakia

Site Status

205.372.27002 Boehringer Ingelheim Investigational Site

Bellville, , South Africa

Site Status

205.372.27001 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

205.372.27004 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

205.372.27008 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

205.372.27006 Boehringer Ingelheim Investigational Site

Centurion, , South Africa

Site Status

205.372.27003 Boehringer Ingelheim Investigational Site

Durban, , South Africa

Site Status

205.372.27005 Boehringer Ingelheim Investigational Site

Pretoria, , South Africa

Site Status

205.372.27007 Boehringer Ingelheim Investigational Site

Somerset West, , South Africa

Site Status

205.372.82010 Boehringer Ingelheim Investigational Site

Anyang, , South Korea

Site Status

205.372.82005 Boehringer Ingelheim Investigational Site

Daegu, , South Korea

Site Status

205.372.82009 Boehringer Ingelheim Investigational Site

Daejoen, , South Korea

Site Status

205.372.82003 Boehringer Ingelheim Investigational Site

Incheon, , South Korea

Site Status

205.372.82008 Boehringer Ingelheim Investigational Site

Jeonbuk, , South Korea

Site Status

205.372.82007 Boehringer Ingelheim Investigational Site

Kwangju, , South Korea

Site Status

205.372.82002 Boehringer Ingelheim Investigational Site

Pusan, , South Korea

Site Status

205.372.82001 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

205.372.82004 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

205.372.82006 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

205.372.34005 Hospital San Pedro de Alcántara

Cáceres, , Spain

Site Status

205.372.34004 Hospital Gregorio Marañón

Madrid, , Spain

Site Status

205.372.34006 Hospital 12 de octubre

Madrid, , Spain

Site Status

205.372.34001 Hospital Mutua Terrassa

Terrassa (Barcelona), , Spain

Site Status

205.372.34002 Hospital Universitario Dr. Peset

Valencia, , Spain

Site Status

205.372.46001 Björknäs Vårdcentral

Boden, , Sweden

Site Status

205.372.46004 Näsets läkargrupp

Höllviken, , Sweden

Site Status

205.372.46005 Lungmedicinska kliniken

Linköping, , Sweden

Site Status

205.372.46006 Lungmedicinska Kliniken

Stockholm, , Sweden

Site Status

205.372.46002 Alnö Vårdcentral

Sundsvall, , Sweden

Site Status

205.372.41002 Boehringer Ingelheim Investigational Site

Lugano, , Switzerland

Site Status

205.372.41003 Boehringer Ingelheim Investigational Site

Montana, , Switzerland

Site Status

205.372.41001 Boehringer Ingelheim Investigational Site

Zurich, , Switzerland

Site Status

205.372.88607 Kaohsiung Medical University Hospital

Kaohsiung City, , Taiwan

Site Status

205.372.88606 National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

205.372.88601 National Taiwan University Hospital

Taipei, , Taiwan

Site Status

205.372.88602 Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

205.372.88603 Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

205.372.88604 Tri-Service General Hospital

Taipei, , Taiwan

Site Status

205.372.88608 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

205.372.88609 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

205.372.88605 Chang Gung Memorial Hosp-Linkou

Taoyuan District, , Taiwan

Site Status

205.372.90006 Gazi Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.

Ankara, , Turkey (Türkiye)

Site Status

205.372.90007 Atatürk Gög. Hastaliklari ve Cerrahisi Egitim Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

205.372.90003 Uludag Universitesi Tip Fakultesi Gogus Hastaliklari

Bursa, , Turkey (Türkiye)

Site Status

205.372.90009 Trakya Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.

Edirne, , Turkey (Türkiye)

Site Status

205.372.90004 Dr. Lütfi Kirdar Egitim ve Arastirma Hastanesi

Istanbul, , Turkey (Türkiye)

Site Status

205.372.90005 Istanbul Universitesi Cerrahpasa Tip Fakultesi

Istanbul, , Turkey (Türkiye)

Site Status

205.372.90001 Izmir Tepecik Gogus Hastaliklari ve Gogus Cerrahisi Hast.

Izmir, , Turkey (Türkiye)

Site Status

205.372.90008 Erciyes Universitesi Tip Fakultesi

Kayseri, , Turkey (Türkiye)

Site Status

205.372.90010 Selcuk Universitesi Tip Fakultesi

Konya, , Turkey (Türkiye)

Site Status

205.372.90002 19 Mayis Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D

Samsun, , Turkey (Türkiye)

Site Status

205.372.44027 Boehringer Ingelheim Investigational Site

Aston Clinton, Aylesbury, , United Kingdom

Site Status

205.372.44022 Boehringer Ingelheim Investigational Site

Carmarthen, , United Kingdom

Site Status

205.372.44002 Boehringer Ingelheim Investigational Site

Chertsey, , United Kingdom

Site Status

205.372.44023 Boehringer Ingelheim Investigational Site

Chesterfield, , United Kingdom

Site Status

205.372.44014 Boehringer Ingelheim Investigational Site

Darlington, , United Kingdom

Site Status

205.372.44009 Boehringer Ingelheim Investigational Site

East Horsley, , United Kingdom

Site Status

205.372.44011 Boehringer Ingelheim Investigational Site

Fowey, , United Kingdom

Site Status

205.372.44003 Boehringer Ingelheim Investigational Site

Frome, , United Kingdom

Site Status

205.372.44026 Boehringer Ingelheim Investigational Site

Greenisland, , United Kingdom

Site Status

205.372.44013 Boehringer Ingelheim Investigational Site

Heywood, , United Kingdom

Site Status

205.372.44016 Boehringer Ingelheim Investigational Site

Isleworth, , United Kingdom

Site Status

205.372.44020 Boehringer Ingelheim Investigational Site

Kirkby in Ashfield, , United Kingdom

Site Status

205.372.44024 Boehringer Ingelheim Investigational Site

Mortimer, , United Kingdom

Site Status

205.372.44001 Boehringer Ingelheim Investigational Site

Nottingham, , United Kingdom

Site Status

205.372.44018 Boehringer Ingelheim Investigational Site

Penzance, , United Kingdom

Site Status

205.372.44021 Boehringer Ingelheim Investigational Site

Plymouth, , United Kingdom

Site Status

205.372.44005 Boehringer Ingelheim Investigational Site

Saint Just, Penzance, , United Kingdom

Site Status

205.372.44007 Boehringer Ingelheim Investigational Site

Sheffield, , United Kingdom

Site Status

205.372.44010 Boehringer Ingelheim Investigational Site

Sneinton, Nottingham, , United Kingdom

Site Status

205.372.44015 Boehringer Ingelheim Investigational Site

St Austell, , United Kingdom

Site Status

205.372.44006 Boehringer Ingelheim Investigational Site

Sunderland, , United Kingdom

Site Status

205.372.44008 Boehringer Ingelheim Investigational Site

Wellingborough, , United Kingdom

Site Status

205.372.44012 Boehringer Ingelheim Investigational Site

Westbury on Trym, , United Kingdom

Site Status

205.372.44028 Boehringer Ingelheim Investigational Site

Windsor, , United Kingdom

Site Status

205.372.44019 Boehringer Ingelheim Investigational Site

Woking, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada China Denmark Finland France Germany Greece Hong Kong Hungary India Ireland Italy Lithuania Malaysia Mexico Netherlands Norway Portugal Singapore Slovakia South Africa South Korea Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020 Sep 17;21(1):240. doi: 10.1186/s12931-020-01482-1.

Reference Type DERIVED
PMID: 32943047 (View on PubMed)

Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, Pavia D, Zhong NS. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010 Oct;104(10):1460-72. doi: 10.1016/j.rmed.2010.06.004.

Reference Type DERIVED
PMID: 20620037 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2006-001009-27

Identifier Type: -

Identifier Source: secondary_id

205.372

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00152984 COMPLETED PHASE4
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
NCT01172808 COMPLETED PHASE3
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02175342 COMPLETED PHASE2
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
NCT00772538 COMPLETED PHASE3
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
NCT01316380 COMPLETED PHASE3
Airway Effects of Tiotropium in Patients With COPD
NCT02683668 COMPLETED PHASE3
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
NCT01126437 COMPLETED PHASE3
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
NCT01533935 COMPLETED PHASE3
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
NCT02296138 COMPLETED PHASE3
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
NCT01694771 COMPLETED PHASE3
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
NCT00776984 COMPLETED PHASE3
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
NCT01533922 COMPLETED PHASE3
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
NCT01696058 COMPLETED PHASE3
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00240435 COMPLETED PHASE3
Tiotropium In Exercise
NCT00525512 COMPLETED PHASE4
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
NCT01525615 COMPLETED PHASE3
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
NCT01172821 COMPLETED PHASE3
Tiotropium Handihaler vs. Tiotropium Respimat in COPD
NCT05838703 WITHDRAWN PHASE2
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
NCT00737100 COMPLETED PHASE2
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05986591 COMPLETED PHASE3
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
NCT01340209 COMPLETED PHASE3
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00292448 COMPLETED PHASE2
Tiotropium (Spiriva) Rehabilitation Study
NCT00274521 COMPLETED PHASE3
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284 COMPLETED PHASE2
Tiotropium Bromide in Cystic Fibrosis
NCT01179347 COMPLETED PHASE3